Benjamin F. Edwards & Company, Inc. Hepion Pharmaceuticals, Inc. Call Options Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
About Hepion Pharmaceuticals, Inc.
- Ticker HEPA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,229,600
- Market Cap $45.7M
- Description
- Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...